InsiderTrades.com logo
The most important AI company you've never heard of
From Manward Press   |   Ad
Because this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products.
Get the full story on this secret AI company poised for massive growth
Dolca Thomas net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Dolca Thomas Biography and Net Worth

Insider of Principia Biopharma
Dr. Dolca Thomas M.D. is the Exec. VP of R&D and Chief Medical Officer at Equillium Inc.

What is Dolca Thomas' net worth?

The estimated net worth of Dolca Thomas is at least $1.68 million as of August 18th, 2020. Dr. Thomas owns 16,826 shares of Principia Biopharma stock worth more than $1,683,441 as of May 16th. This net worth approximation does not reflect any other assets that Dr. Thomas may own. Learn More about Dolca Thomas' net worth.

How do I contact Dolca Thomas?

The corporate mailing address for Dr. Thomas and other Principia Biopharma executives is 220 East Grand Avenue, SOUTH SAN FRANCISCO CA, 94080. Principia Biopharma can also be reached via phone at 650-416-7700 and via email at [email protected]. Learn More on Dolca Thomas' contact information.

Has Dolca Thomas been buying or selling shares of Principia Biopharma?

Dolca Thomas has not been actively trading shares of Principia Biopharma within the last three months. Most recently, Dolca Thomas sold 15,000 shares of the business's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $100.00, for a transaction totalling $1,500,000.00. Following the completion of the sale, the insider now directly owns 16,826 shares of the company's stock, valued at $1,682,600. Learn More on Dolca Thomas' trading history.

Who are Principia Biopharma's active insiders?

Principia Biopharma's insider roster includes Martin Babler (CEO), Alan Colowick (Director), and Dolca Thomas (Insider). Learn More on Principia Biopharma's active insiders.

Dolca Thomas Insider Trading History at Principia Biopharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/18/2020Sell15,000$100.00$1,500,000.0016,826View SEC Filing Icon  
7/15/2020Sell15,000$80.07$1,201,050.00View SEC Filing Icon  
12/19/2019Sell495$60.00$29,700.00View SEC Filing Icon  
See Full Table

Dolca Thomas Buying and Selling Activity at Principia Biopharma

This chart shows Dolca Thomas's buying and selling at Principia Biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Principia Biopharma Company Overview

Principia Biopharma logo
Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $100.05
Low: $100.05
High: $100.05

50 Day Range

MA: $100.05
Low: $99.95
High: $100.27

2 Week Range

Now: $100.05
Low: $25.35
High: $101.89

Volume

N/A

Average Volume

729,676 shs

Market Capitalization

$3.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86
The most important AI company you've never heard of
From Manward Press   |   Ad
Because this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products.
Get the full story on this secret AI company poised for massive growth